PI4KIIIβ is a therapeutic target in chromosome 1q–amplified lung adenocarcinoma

Xiaochao Tan(Tulane University), Jonathan M. Kurie(The University of Texas MD Anderson Cancer Center), William K. Russell(The University of Texas Medical Branch at Galveston), Don L. Gibbons(The University of Texas MD Anderson Cancer Center), Ingrid Choong(Stanford Medicine), Dzifa Y. Duose(The University of Texas MD Anderson Cancer Center), Kaustabh Basu(Stanford Medicine), Ignacio I. Wistuba(The University of Texas MD Anderson Cancer Center), B. Leticia Rodriguez(The University of Texas MD Anderson Cancer Center), Veronica Zheng(The University of Texas MD Anderson Cancer Center), Neus Bota‐Rabassedas(The University of Texas MD Anderson Cancer Center), Edward A. Pham(Stanford Medicine), Barbara Mino(The University of Texas MD Anderson Cancer Center), Jamal Hill(The University of Texas MD Anderson Cancer Center), Chad J. Creighton(Baylor College of Medicine), Caitlin L. Grzeskowiak(Baylor College of Medicine), Hou‐Fu Guo(University of Kentucky HealthCare), Powel H. Brown(The University of Texas MD Anderson Cancer Center), Priyam Banerjee(The University of Texas MD Anderson Cancer Center), Khanh Cong Nguyen(National Institute Of Hygiene And Epidemiology), Maria Gabriela Raso, Kevan M. Shokat(Howard Hughes Medical Institute), Florentine U. Rutaganira(Howard Hughes Medical Institute), Abhijit Mazumdar(The University of Texas MD Anderson Cancer Center), Jeffrey S. Glenn(Stanford University), Grace Lam(Stanford Medicine), Xin Liu(The University of Texas MD Anderson Cancer Center), Lei Shi(Sun Yat-sen University), Yu Jiang(The University of Texas MD Anderson Cancer Center), Mark Smith(Stanford Medicine), Kenneth L. Scott(Dana-Farber Cancer Institute), David H. Peng(The University of Texas MD Anderson Cancer Center), Luisa M. Solis(The University of Texas MD Anderson Cancer Center), Carmen Behrens
Science Translational Medicine
January 22, 2020
Cited by 68


Related Papers